SG11201908679QA - Isomerically pure 18f-labelled tetrahydrofolates - Google Patents
Isomerically pure 18f-labelled tetrahydrofolatesInfo
- Publication number
- SG11201908679QA SG11201908679QA SG11201908679QA SG11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- labelled
- pct
- isomerically pure
- tetrahydrofolates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17161884 | 2017-03-20 | ||
| PCT/EP2018/056806 WO2018172243A1 (en) | 2017-03-20 | 2018-03-19 | Isomerically pure 18f-labelled tetrahydrofolates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908679QA true SG11201908679QA (en) | 2019-10-30 |
Family
ID=58387756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908679Q SG11201908679QA (en) | 2017-03-20 | 2018-03-19 | Isomerically pure 18f-labelled tetrahydrofolates |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3601288B1 (ja) |
| JP (1) | JP7204662B2 (ja) |
| KR (1) | KR102648945B1 (ja) |
| CN (1) | CN110431141B (ja) |
| AU (1) | AU2018237784B2 (ja) |
| CA (1) | CA3057042A1 (ja) |
| DK (1) | DK3601288T3 (ja) |
| EA (1) | EA201992180A1 (ja) |
| ES (1) | ES2893303T3 (ja) |
| IL (1) | IL269059B (ja) |
| PL (1) | PL3601288T3 (ja) |
| PT (1) | PT3601288T (ja) |
| SG (1) | SG11201908679QA (ja) |
| WO (1) | WO2018172243A1 (ja) |
| ZA (1) | ZA201906877B (ja) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2150514T (pt) | 2007-04-11 | 2019-02-01 | Merck & Cie | Folatos etiquetados com 18f |
| DK2254890T3 (da) | 2008-02-20 | 2015-07-13 | Gnosis Spa | Fremgangsmåde til diastereomerisk racematspaltning af methyltetrahydrofolsyre |
| US20130034496A1 (en) | 2011-08-04 | 2013-02-07 | University Of Iowa Research Foundation | Positron emission tomography tracer |
| CA2870124C (en) | 2012-05-08 | 2021-02-16 | Merck & Cie | 18f-labelled folate/antifolate analogues |
-
2018
- 2018-03-19 EA EA201992180A patent/EA201992180A1/ru unknown
- 2018-03-19 JP JP2019551384A patent/JP7204662B2/ja active Active
- 2018-03-19 KR KR1020197030478A patent/KR102648945B1/ko active IP Right Grant
- 2018-03-19 ES ES18710887T patent/ES2893303T3/es active Active
- 2018-03-19 PL PL18710887T patent/PL3601288T3/pl unknown
- 2018-03-19 AU AU2018237784A patent/AU2018237784B2/en active Active
- 2018-03-19 EP EP18710887.3A patent/EP3601288B1/en active Active
- 2018-03-19 WO PCT/EP2018/056806 patent/WO2018172243A1/en unknown
- 2018-03-19 CN CN201880018678.9A patent/CN110431141B/zh active Active
- 2018-03-19 DK DK18710887.3T patent/DK3601288T3/da active
- 2018-03-19 SG SG11201908679Q patent/SG11201908679QA/en unknown
- 2018-03-19 CA CA3057042A patent/CA3057042A1/en active Pending
- 2018-03-19 PT PT187108873T patent/PT3601288T/pt unknown
-
2019
- 2019-09-02 IL IL269059A patent/IL269059B/en unknown
- 2019-10-18 ZA ZA2019/06877A patent/ZA201906877B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3601288T (pt) | 2021-07-20 |
| EP3601288A1 (en) | 2020-02-05 |
| ES2893303T3 (es) | 2022-02-08 |
| WO2018172243A1 (en) | 2018-09-27 |
| IL269059B (en) | 2021-12-01 |
| US20200306390A1 (en) | 2020-10-01 |
| EA201992180A1 (ru) | 2020-04-23 |
| DK3601288T3 (da) | 2021-07-05 |
| ZA201906877B (en) | 2021-06-30 |
| EP3601288B1 (en) | 2021-04-21 |
| KR102648945B1 (ko) | 2024-03-18 |
| JP2020511477A (ja) | 2020-04-16 |
| IL269059A (en) | 2019-11-28 |
| CA3057042A1 (en) | 2018-09-27 |
| JP7204662B2 (ja) | 2023-01-16 |
| AU2018237784A1 (en) | 2019-11-07 |
| AU2018237784B2 (en) | 2022-04-21 |
| CN110431141A (zh) | 2019-11-08 |
| CN110431141B (zh) | 2022-12-30 |
| PL3601288T3 (pl) | 2021-11-08 |
| KR20190130607A (ko) | 2019-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201806512VA (en) | Copanlisib biomarkers | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201900043TA (en) | Antibody formulations | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11201811246RA (en) | Novel silybum marianum achene extract and uses thereof in dermatology and dermo-cosmetics | |
| SG11201907844TA (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders |